dbsable
|
|
|
Articles for Forbes are here.
Wharton Magazine pieces are here (link fixed)
Entrepreneurship in Biotechnology at Columbia University is here
@dbsable on twittter is here
Video content is here
Draft chapters for Democratizing IVF: Using Science, Medicine, And Engineering (And Venture Capital) To Help Build Families are on my Medium page here
David Sable MD is a life sciences portfolio manager.
After graduating from the Wharton School and the University of Pennsylvania School of Medicine, he trained in obstetrics and gynecology at New York Hospital - Cornell Medical Center, and in reproductive endocrinology at the Brigham and Women's Hospital. He co-founded and served as director of the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey, was founder of Assisted Reproductive Medical Technologies, which was acquired by Saint Barnabas in 1999, and co-founder of Reprogenetics, acquired by Cooper Surgical in 2015.
Dr. Sable is an adjunct in the department of biology at Columbia University, and teaches “Entrepreneurship in Biotechnology” at Columbia’s Graduate School of Arts and Sciences. He has lectured on healthcare investing, policy, and biotechnology business development at the Wharton School, NYU, Rockefeller University and Rutgers; has delivered keynote addresses to the American Fertility Society, the Texas Fertility Society and the Mexican Fertility Society; and appeared on the CBS Morning News, ABC World News Tonight, NY1 News and PBS’ Nova to discuss innovation in reproductive medicine. He serves as a director for Celmatix, and Hamilton Thorne Ltd., is an advisor and board observer for TMRW Life Sciences, has served as a board member for Genenews Inc, Ohana Biosciences, MedAnswers, and for the nonprofit advocacy organization RESOLVE, and on the medical and scientific advisory boards of Ovascience, and Progyny. In addition to his academic publications, he has written for the Newark Star-Ledger, Yoga Journal, Xconomy, Genetic Engineering and Biotechnology News, The Timmerman Report, Life Science Leader, Wharton Magazine, and Forbes.
Wharton Magazine pieces are here (link fixed)
Entrepreneurship in Biotechnology at Columbia University is here
@dbsable on twittter is here
Video content is here
Draft chapters for Democratizing IVF: Using Science, Medicine, And Engineering (And Venture Capital) To Help Build Families are on my Medium page here
David Sable MD is a life sciences portfolio manager.
After graduating from the Wharton School and the University of Pennsylvania School of Medicine, he trained in obstetrics and gynecology at New York Hospital - Cornell Medical Center, and in reproductive endocrinology at the Brigham and Women's Hospital. He co-founded and served as director of the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey, was founder of Assisted Reproductive Medical Technologies, which was acquired by Saint Barnabas in 1999, and co-founder of Reprogenetics, acquired by Cooper Surgical in 2015.
Dr. Sable is an adjunct in the department of biology at Columbia University, and teaches “Entrepreneurship in Biotechnology” at Columbia’s Graduate School of Arts and Sciences. He has lectured on healthcare investing, policy, and biotechnology business development at the Wharton School, NYU, Rockefeller University and Rutgers; has delivered keynote addresses to the American Fertility Society, the Texas Fertility Society and the Mexican Fertility Society; and appeared on the CBS Morning News, ABC World News Tonight, NY1 News and PBS’ Nova to discuss innovation in reproductive medicine. He serves as a director for Celmatix, and Hamilton Thorne Ltd., is an advisor and board observer for TMRW Life Sciences, has served as a board member for Genenews Inc, Ohana Biosciences, MedAnswers, and for the nonprofit advocacy organization RESOLVE, and on the medical and scientific advisory boards of Ovascience, and Progyny. In addition to his academic publications, he has written for the Newark Star-Ledger, Yoga Journal, Xconomy, Genetic Engineering and Biotechnology News, The Timmerman Report, Life Science Leader, Wharton Magazine, and Forbes.